We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Novel Presepsin Assay Evaluated Using Automated Immunoanalyzer

By LabMedica International staff writers
Posted on 27 Jul 2022
Print article
Image: The HISCL Presepsin Assay Kit can be used with its Automated Immunoassay System HISCL-5000/2000i/800 for immunochemistry testing (Photo courtesy of Sysmex Corporation)
Image: The HISCL Presepsin Assay Kit can be used with its Automated Immunoassay System HISCL-5000/2000i/800 for immunochemistry testing (Photo courtesy of Sysmex Corporation)

Biomarkers that reflect systemic responses during sepsis have been studied continuously, and there are various surrogate markers for the diagnosis of sepsis. Procalcitonin (PCT), C-reactive protein (CRP), cytokines, and chemokines have been studied extensively under the previous and revised sepsis definitions.

A soluble CD14 molecule (presepsin) has been developed and applied toward the diagnosis and prognosis of sepsis. Presepsin is a soluble CD14 molecule that is cleaved and released into the general circulation after activation by a monocyte or macrophage. Pathogen-associated molecular species such as lipopolysaccharide (LPS) from gram-negative bacteria can bind to serum lipoprotein-binding protein, both of which bind to CD14.

Biomedical Scientists at the Seoul St. Mary's Hospital, College of Medicine (Seoul, South Korea) collected samples from sepsis patients visiting the emergency department were collected before a treatment. Sepsis was diagnosed using a SOFA score with suspected bacterial infection. Reference intervals were analyzed and 124 subjects without underlying disease or prescribed medication from electronic medical records were selected.

For method comparison, 87 samples from suspected sepsis patients were collected within 24 hours from blood drawn and refrigerated at −80 °C for method comparison in duplicate. A total of 84 plasma from EDTA samples was analyzed with the chemiluminescence enzyme immunoassay by both Sysmex HISCL-5000 (Sysmex Corporation, Kobe, Japan) and PATHFAST (LSI Medience Corporation, Tokyo, Japan). For Sysmex HISCL-5000, the measurement range was from 0 to 30,000 pg/mL and for PATHFAST, the measurement range was from 0 to 20,000 pg/mL. Precision, linearity, limit of blank/limit of detection, method comparisons, and reference intervals were evaluated.

The investigators reported that precision using a 20×2×2 protocol for low (306 pg/mL) and high (1,031 pg/mL) levels resulted in within-laboratory standard deviation (95% confidence interval [CI]) and coefficient of variation (CV) %, which were as follows: 15.3 (13.1–18.7), 5.5% and 47.7, (40.5–58.1), 6.4%, respectively. Linearity using patient samples and calibrators were measured from 201 to 16,177 and 188 to 30,000 pg/mL, respectively. The correlation coefficient (95% CI) was 0.869 (0.772–0.927) with statistical significance. Reference intervals from 120 normal healthy subjects showed that 300 pg/mL was the cut off. Presepsin tended to show a higher value at higher ages and in males. A method comparison between Sysmex HISCL-5000 and PATHFAST was performed and the correlation coefficient was 0.979, which showed a high correlation coefficient.

The authors concluded that presepsin analyzed by HISCL-5000 showed reliable analytical performance that could be used in clinical settings. A wide range of analytical measurements ranging from 200 to 30,000 pg/mL was verified. As presepsin showed positive and negative correlations with hematocrit and renal function, careful interpretation is required for patients with underlying diseases involving red blood cells or kidneys. The study was published on July 23 2022 in the Journal of Clinical Laboratory Analysis.

Related Links:
Seoul St. Mary's Hospital, College of Medicine 
Sysmex Corporation 
LSI Medience Corporation 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Molecular Diagnostics

view channel
Image: The fastGEN BCR::ABL1 Cancer kit offers a way to personalize treatment strategies for leukemia (Photo courtesy of BioVendor MDx)

First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment

The BCR::ABL1 fusion gene plays a key role in the pathogenesis of several blood cancers, particularly chronic myeloid leukemia (CML). This gene results from a chromosomal translocation that causes constitutive... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The new method is quick and easy, and can also be used by non-medical personnel. (Photo courtesy of Zoratto et al. Advanced Science 2024, edited)

New Blood Test Device Modeled on Leeches to Help Diagnose Malaria

Many individuals have a fear of needles, making the experience of having blood drawn from their arm particularly distressing. An alternative method involves taking blood from the fingertip or earlobe,... Read more